DNA初免与NTV加强序贯方案可同时诱导体液和细胞免疫对抗寨卡与痘病毒
该研究构建了表达寨卡病毒prME或E糖蛋白的DNA疫苗和非复制型痘苗病毒(NTV)疫苗,在BABL/c小鼠中比较同源(DNA/DNA、NTV/NTV)与异源(DNA/NTV)初免-加强方案的免疫效果。结果显示各方案诱导相似水平的抗E IgG和中和抗体,但DNA/NTV异源方案诱导的E特异性T细胞反应显著更高,且能同时诱导体液和细胞免疫对抗痘苗病毒,并鉴定出一个新的H-2d限制性CD8 T细胞表位。
要点
- DNA/NTV异源初免-加强方案诱导的E特异性T细胞反应显著高于同源方案。
- 各免疫方案均诱导相似水平的抗E IgG和中和抗体。
- DNA/NTV方案可同时诱导体液和细胞免疫对抗寨卡病毒和痘病毒。
核心结论
- DNA-prME初免与NTV-E加强的异源方案可作为同时预防寨卡病毒和正痘病毒感染的双价疫苗候选策略。
研究设计与样本
- 研究在BABL/c小鼠中比较表达寨卡病毒prME或E糖蛋白的DNA疫苗和NTV疫苗的同源(DNA/DNA、NTV/NTV)与异源(DNA/NTV)初免-加强免疫方案。
主要发现
- 各免疫方案在小鼠中诱导相似水平的抗E IgG和中和抗体(微量中和试验)。
- DNA/NTV异源初免-加强方案诱导的E特异性T细胞反应显著高于同源方案。
- DNA/NTV方案免疫小鼠可检测到针对痘苗病毒的中和抗体和T细胞免疫反应,而NTV/NTV同源方案小鼠抗痘苗病毒IgG和中和抗体水平更高。
- 在寨卡病毒E蛋白中鉴定出新的H-2d限制性CD8 T细胞表位VRSYCYEASISDMAS。
临床怎么用
- 提示可采用DNA初免联合NTV加强的序贯免疫策略开发同时针对寨卡病毒和正痘病毒的双价疫苗。
局限性
- 研究仅在小鼠中进行,尚未在人体中验证免疫原性和保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Zika virus (ZIKV) and poxvirus infection are considered as public health emergencies, necessitating the development of effective vaccines. Here, we report novel recombinant DNA-based and non-replicating vaccinia virus (NTV)-based vaccine candidates that express the precursor membrane-envelope (prME) or envelope (E) glycoproteins of ZIKV. After immunization of BABL/c mice with the vaccines using a homologous protocol (DNA/DNA, NTV/NTV) or heterogeneous (DNA/NTV) protocol, a similar level of anti-E IgG and neutralizing antibodies (microneutralization test) were detected in the mice. However, a significantly higher level of E-specific T cell responses was elicited in mice when a heterogeneous prime-boost protocol was used (DNA/NTV) with either the DNA-based or NTV-based vaccines. Furthermore, neutralizing antibodies and a T cell immune response against the vaccinia virus (VV) were detected in mice that were subjected to the prime-boost protocol (DNA/NTV), whereas those subjected to a homologous NTV/NTV protocol had higher levels of anti-VV IgG and neutralizing antibodies. Lastly, a novel H-2d-restricted CD8 T-cell epitope, VRSYCYEASISDMAS, was identified in the ZIKV E protein. These data demonstrate proof of concept of a bivalent vaccine candidate against ZIKV and orthopoxvirus, and support the use of DNA-prME prime and NTV-E boost protocols to protect against ZIKV and orthopoxvirus infections.
引用
- Zhan Y, Deng Y, Huang B, et al. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine. 2019. PMID: 30851967. doi:10.1016/j.vaccine.2019.02.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。